What Is The
BBDRisk Dx® Test?


BBDRisk Dx® is the first genomic risk test designed specifically for women diagnosed with breast masses that have one or more of the following: Atypical Ductal Hyperplasias (ADH), Atypical Lobular Hyperplasia (ALH), Usual Ductal Hyperplasias (UDH), Papilloma and Sclerosing Adenosis. The test assays a unique set of cancer biomarker proteins, MMP-1, CEACAM6, HYAL1 and HEC1, in the biopsied tissue and predicts the likelihood of developing breast cancer. The test is based on over a decade of Research and Development. Detailed information about the test can be found in the following links:

. Atypical and Non-atypical Hyperplasias and Breast Cancer Risk
. NEW GENOMIC TEST, BBDRisk Dx®, TO ASSESS RISK
. BBDRisk Dx® Test in Medical Management of Hyperplasias
. Science Behind BBDRisk Dx® Test Development